Tag:Food and Drug Administration (FDA)

Professor Lietzan Discusses Executive Order’s Possible Impact on Food and Drug Administration

February 1st, 2017

Professor Erika Lietzan was quoted at length today in an article published by the Regulatory Affairs Professional Society (RAPS) about the impact of President Trump’s January 30 “two-for-one” executive order on the U.S. Food and Drug Administration

Read More

Proposed Legislation Reflects a Misunderstanding of Drug Safety Programs: Professor Lietzan in The Hill

November 21st, 2016

The Hill published an op-ed written by Professor Erika Lietzan on the proposed “CREATES Act.” In the article, Professor Lietzan explains that the proposed legislation reflects a misunderstanding of the drug safety programs required by the Food

Read More

Mizzou Law Faculty Member Receives Thomas Edison Innovation Fellowship

November 16th, 2016

Professor Erika Lietzan has been awarded a second Thomas Edison Innovation Fellowship from the Center for the Protection of Intellectual Property at George Mason University’s Antonin Scalia Law School. The Thomas Edison Fellowship is a year-long non-resident

Read More

FDA’s Approval of Drug Fell Within Legal Authority: Professor Lietzan

October 7th, 2016

Professor Erika Lietzan was recently quoted by STAT regarding the Food & Drug Administration’s recent decision to grant accelerated approval to the first drug for Duchenne muscular dystrophy. The decision has attracted criticism, because approval was based

Read More

Professor Lietzan Cowrites Chapter in FDA in the 21st Century

September 10th, 2015

Professor Erika Lietzan recently cowrote an essay in a book published by Columbia University Press, FDA in the 21st Century, with Professor Henry Grabowski of Duke University. The book chapter, “FDA Regulation of Biosimilars,” discusses the Biologics

Read More